Please login to the form below

Not currently logged in
Email:
Password:

mirabegron

This page shows the latest mirabegron news and features for those working in and with pharma, biotech and healthcare.

Urovant slips on phase 3 incontinence drug data

Urovant slips on phase 3 incontinence drug data

Vibegron was licensed from Merck &Co/MSD in 2017 and is billed as an improved version of Astellas’ Myrbetriq/Betmiga (mirabegron), which was the first beta3-adrenergic agonist to reach the

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new

  • Interview: Ken Jones, Astellas Pharma Europe Interview: Ken Jones, Astellas Pharma Europe

    Urology is a key strategic area for Astellas and we have a strong pipeline in this therapy area; we are currently getting prepared with Mirabegron, a drug to treat overactive bladder,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

COVID-19 is redefining the value of ‘critical jobs’: An opportunity for social care?
...
How to keep your weight under control during lockdown
...
Brands stepping up to show solidarity during COVID-19
The brands that are stepping up to show solidarity during COVID-19 will be those that are remembered long after pandemic passes....

Infographics